Proinsulin processing generates two principal intermediate molecules—des-31,32-proinsulin and des-64,65-proinsulin—along with minor split-proinsulin forms. These intermediates arise from incomplete enzymatic cleavage of the 86‑amino‑acid precursor and retain large peptide segments common to both insulin and C‑peptide. Because they share critical epitope structures with mature insulin, an immunoassay that has not been carefully optimized for specificity will detect these intermediates and produce a falsely elevated insulin reading.
Circulating proinsulin intermediates can contribute 10–15 % of the total immunoreactive insulin signal in a fasting sample. Therefore, every IVD raw material choice—from capture and detection antibodies to recombinant calibration standards—must be validated against these structural precursors if the assay is to measure mature insulin specifically and avoid clinically misleading results.
How Proinsulin Is Processed—and Where the Intermediates Come From
Proinsulin is the single-chain precursor that must be cut twice to liberate mature insulin and C‑peptide. The enzymatic cleavage steps are sequential and occasionally incomplete, leaving behind the intermediates that challenge immunoassay design.
The Major Pathway: Des‑31,32‑Proinsulin
The first cleavage, catalyzed by prohormone convertase 1 (PC1), occurs at the B‑chain/C‑peptide junction.
This cut removes the dibasic Arg‑Arg pair, yielding des‑31,32‑proinsulin—a molecule that still contains the entire A‑chain, the connecting C‑peptide, and the already‑cleaved B‑chain held together by disulfide bonds.
Because the processing stop point leaves the insulin A‑ and B‑chains essentially intact, this intermediate retains strong insulin‑like immunoreactivity.
The Minor Pathway and Split Forms
A second cleavage at the C‑peptide/A‑chain junction is performed by prohormone convertase 2 (PC2) in partnership with carboxypeptidase‑H.
When this cut happens before the first junction is fully processed, the result is des‑64,65‑proinsulin (the minor intermediate) or transient 32,33‑split / 65,66‑split species.
All these forms preserve a continuous polypeptide backbone that includes the insulin A‑ and B‑chain sequences, rendering them cross‑reactive with many insulin‑directed antibodies.
Why the Intermediates Persist in Circulation
Processing is not 100 % efficient; a fraction of proinsulin escapes complete conversion and enters the bloodstream along with the mature hormones.
In insulin‑resistant states, beta‑cells are driven to secrete more proinsulin‑rich granules, raising the proportion of circulating intermediates further.
Consequently, any insulin assay that recognizes these molecules risks over‑reporting the true concentration of biologically active insulin.
The Cross‑Reactivity Challenge in Insulin Immunoassays
The structural overlap between mature insulin and its precursors lies at the heart of the specificity problem. Understanding the molecular basis of that overlap guides how raw materials must be selected.
Shared Epitope Architecture
Mature insulin consists of an A‑chain and a B‑chain connected by two inter‑chain disulfide bonds.
In proinsulin and its des‑intermediates, those same A‑ and B‑chain sequences are present but are bridged by the C‑peptide segment.
Monoclonal antibodies raised against intact insulin often recognize conformational or linear epitopes that are preserved—or only slightly distorted—in the precursor molecules.
The Clinical Impact of Unchecked Cross‑Reactivity
When an assay cross‑reacts with proinsulin and des‑intermediates, it can overestimate insulin by 10–15 %, and in hyperproinsulinemic conditions the error can be far greater.
For diabetes classification and research, this blurring of the insulin signal confounds the assessment of beta‑cell function, insulin sensitivity, and the diagnosis of insulinoma.
Removing this interference is therefore not just a technical nuance—it is a prerequisite for delivering a diagnostically meaningful result.
Raw Material Selection for IVD Assay Specificity
Developers must choose antibody clones, recombinant proteins, and calibrator formats that discriminate mature insulin from its immediate precursors. This selection process turns on deliberate screening strategies.
Antibody Screening Panels Must Include All Major Intermediates
Screening solely against intact proinsulin is insufficient; des‑31,32‑proinsulin and des‑64,65‑proinsulin must be part of the cross‑reactivity panel.
High‑quality recombinant forms of each intermediate allow the developer to quantify the percentage of signal generated by each species relative to mature insulin.
The goal is to identify antibody pairs whose binding is abolished or drastically reduced when the C‑peptide bridge is present, ideally targeting the free ends of the mature hormone that are only exposed after full processing.
Recombinant Standards and Calibrator Integrity
The same intermediates can contaminate recombinant insulin preparations if the production host—typically yeast or E. coli—fails to completely process the precursor.
IVD manufacturers must source recombinant insulin standards with certified purity, free from proinsulin and des‑intermediates, so that the calibration curve reflects genuine mature insulin and does not itself introduce bias.
Bridging the assay with a characterized reference material (e.g., WHO International Standard) further anchors the measurement in a defined specificity profile.
Defining and Communicating Cross‑Reactivity Profiles
Once candidate antibodies are selected, the final assay must be tested with clinically relevant concentrations of each intermediate to establish a quantified cross‑reactivity limit.
For a mature‑insulin‑specific assay, cross‑reactivity with intact proinsulin and des‑intermediates should typically be below 0.1–0.5 %, and this performance must be clearly documented in the kit insert.
Such transparency gives clinical laboratories confidence that the insulin value they report reflects only the biologically active hormone.
Understanding the Trade‑offs and Common Pitfalls
Striving for maximum specificity is not without consequences. Developers must weigh several practical factors to avoid introducing new problems while solving the original one.
- Specificity versus sensitivity: Antibodies that bind the mature insulin termini with exceptionally high stringency may have lower affinity than those that tolerate the precursor forms. The resulting assay could sacrifice sensitivity or precision at low insulin concentrations.
- Recognition of insulin analogs: If the assay is intended to detect therapeutic insulin analogs (e.g., insulin lispro, aspart), an epitope that is perfectly selective for endogenous insulin may miss the analogs entirely. Multiple antibody clones or a panel approach may be required.
- Cost and supply of intermediate proteins: High‑quality recombinant des‑31,32‑ and des‑64,65‑proinsulin are specialty reagents that can be expensive and limited in supply, making extensive screening a logistical challenge.
- One assay cannot serve all purposes: A highly specific insulin assay may not offer the same clinical utility in scenarios where proinsulin measurement itself is valuable, such as insulinoma or beta‑cell stress markers. Laboratories must understand the intended use and may need a separate proinsulin‑specific assay for a complete picture.
Making the Right Choice for Your Assay Goal
Your raw material selection strategy must align with the clinical question the assay is meant to answer. Use the following decision points to guide your screening effort.
- If your primary focus is accurate insulin quantification for diabetes classification and insulin sensitivity indices: Prioritize monoclonal antibody pairs that exhibit less than 0.2 % cross‑reactivity with intact proinsulin, des‑31,32‑proinsulin, and des‑64,65‑proinsulin, and validate this with recombinant antigen panels.
- If your assay also needs to detect exogenous insulin analogs: Screen a broader panel that includes the analogs of interest alongside the processing intermediates, accepting that a single antibody may not suffice and a carefully designed combination of capture and detection reagents may be necessary.
- If you are developing a C‑peptide assay to assess beta‑cell function: Ensure the antibodies do not cross‑react with proinsulin or split‑proinsulin forms, and confirm that the assay recovers C‑peptide independently of the high‑molecular‑weight precursors that coexist in the sample.
- If your goal is a research‑grade assay that quantifies proinsulin and its intermediates separately: Consider a multiplex approach or separate assays, each validated against the full spectrum of precursor molecules to avoid mutual interference.
By mapping the structural intermediates early in raw material selection and rigorously testing cross‑reactivity, you build an insulin assay that delivers the accuracy and diagnostic confidence that clinicians and patients depend on.
Summary Table:
| Intermediate Molecule | Cleavage Site / Primary Enzyme | Key Structural Feature | Immunoassay Cross-Reactivity Risk |
|---|---|---|---|
| Des-31,32-proinsulin | B-chain/C-peptide junction (PC1) | Major intermediate; retains full A-chain, C-peptide, and B-chain | High risk; causes up to 10–15% false elevation in unoptimized assays |
| Des-64,65-proinsulin | C-peptide/A-chain junction (PC2) | Minor intermediate; preserves A/B chain epitope structures | Moderate to high risk with A/B-chain-directed antibodies |
| Split-proinsulin forms | Transient / incomplete cleavage | Intact polypeptide backbone bridging A and B chains | Cross-reacts if antibody target isn't strictly terminal-specific |
Achieve Superior Assay Specificity with CamelBio
Eliminating cross-reactivity from proinsulin intermediates requires rigorously validated, high-purity reagents. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Whether you are screening monoclonal antibody pairs or sourcing high-integrity recombinant standards, our team is ready to accelerate your diagnostic development. Contact CamelBio today to discuss your raw material and assay development needs!